Inventiva announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (CTTQ), a subsidiary of Sino Biopharm. This payment follows the successful settlement of the second tranche of Inventiva's structured financing, which provided €115.6 million in gross proceeds.
Under the amended CTTQ License Agreement, Inventiva remains eligible to receive up to an additional $265 million in clinical, regulatory, and commercial milestone payments, along with low single-digit royalties on future net sales of lanifibranor in Greater China. Lanifibranor previously received Breakthrough Therapy Designation from the Chinese National Medical Products Administration in December 2023.
CTTQ is actively participating in Inventiva's ongoing NATiV3 pivotal Phase 3 clinical trial, with over 60 sites across mainland China. CTTQ has also completed a Phase I bridging study, confirming no significant ethnic differences, which paves the way for seeking regulatory approval in China based on the results of the NATiV3 trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.